Literature DB >> 8341653

"Diabodies": small bivalent and bispecific antibody fragments.

P Holliger1, T Prospero, G Winter.   

Abstract

Bivalent and bispecific antibodies and their fragments have immense potential for practical application. Here we describe the design of small antibody fragments with two antigen-binding sites. The fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) on the same polypeptide chain (VH-VL). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. As indicated by a computer graphic model of the dimers, the two pairs of domains can pack together with the antigen-binding sites pointing in opposite directions. The dimeric antibody fragments, or "diabodies," can be designed for bivalent or bispecific interactions. Starting from the monoclonal antibodies NQ11.7.22 (NQ11) and D1.3 directed against the hapten phenyloxazolone and hen egg lysozyme, respectively, we built bivalent fragments (VHNQ11-VLNQ11)2 and (VHD1.3-VLD1.3)2 and bispecific fragments VHNQ11-VLD1.3 and VHD1.3-VLNQ11. The fragments were expressed by secretion from bacteria and shown to bind specifically to the hapten and/or antigen. Those with 5- and 15-residue linkers had similar binding affinities to the parent antibodies, but a fragment with the VH domain joined directly to the VL domain was found to have slower dissociation kinetics and an improved affinity for hapten. Diabodies offer a ready means of constructing small bivalent and bispecific antibody fragments in bacteria.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8341653      PMCID: PMC46948          DOI: 10.1073/pnas.90.14.6444

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Phage antibodies: filamentous phage displaying antibody variable domains.

Authors:  J McCafferty; A D Griffiths; G Winter; D J Chiswell
Journal:  Nature       Date:  1990-12-06       Impact factor: 49.962

2.  Antibody framework residues affecting the conformation of the hypervariable loops.

Authors:  J Foote; G Winter
Journal:  J Mol Biol       Date:  1992-03-20       Impact factor: 5.469

3.  Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains.

Authors:  H R Hoogenboom; A D Griffiths; K S Johnson; D J Chiswell; P Hudson; G Winter
Journal:  Nucleic Acids Res       Date:  1991-08-11       Impact factor: 16.971

4.  Kinetic maturation of an immune response.

Authors:  J Foote; C Milstein
Journal:  Nature       Date:  1991-08-08       Impact factor: 49.962

Review 5.  Man-made antibodies.

Authors:  G Winter; C Milstein
Journal:  Nature       Date:  1991-01-24       Impact factor: 49.962

6.  Improving the antigen affinity of an antibody Fv-fragment by protein design.

Authors:  L Riechmann; M Weill; J Cavanagh
Journal:  J Mol Biol       Date:  1992-04-20       Impact factor: 5.469

7.  Formation of a bispecific antibody by the use of leucine zippers.

Authors:  S A Kostelny; M S Cole; J Y Tso
Journal:  J Immunol       Date:  1992-03-01       Impact factor: 5.422

8.  Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli.

Authors:  P Pack; A Plückthun
Journal:  Biochemistry       Date:  1992-02-18       Impact factor: 3.162

9.  Secretion and in vivo folding of the Fab fragment of the antibody McPC603 in Escherichia coli: influence of disulphides and cis-prolines.

Authors:  A Skerra; A Plückthun
Journal:  Protein Eng       Date:  1991-12

10.  Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene.

Authors:  M R Shalaby; H M Shepard; L Presta; M L Rodrigues; P C Beverley; M Feldmann; P Carter
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

View more
  168 in total

Review 1.  Generation and production of engineered antibodies.

Authors:  Sergey M Kipriyanov; Fabrice Le Gall
Journal:  Mol Biotechnol       Date:  2004-01       Impact factor: 2.695

2.  Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibody.

Authors:  Barbara E Power; Larissa Doughty; Deborah R Shapira; John E Burns; Ann M Bayly; Joanne M Caine; Zhanqi Liu; Andrew M Scott; Peter J Hudson; Alexander A Kortt
Journal:  Protein Sci       Date:  2003-04       Impact factor: 6.725

3.  Improved stability of multivalent antibodies containing the human collagen XV trimerization domain.

Authors:  Angel M Cuesta; David Sánchez-Martín; Ana Blanco-Toribio; Maider Villate; Kelly Enciso-Álvarez; Ana Alvarez-Cienfuegos; Noelia Sainz-Pastor; Laura Sanz; Francisco J Blanco; Luis Alvarez-Vallina
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

4.  IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA.

Authors:  Johan Nilvebrant; D Cameron Dunlop; Aroop Sircar; Thierry Wurch; Emilia Falkowska; Janice M Reichert; Gustavo Helguera; Emily C Piccione; Simon Brack; Sven Berger
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

Review 5.  Dual targeting strategies with bispecific antibodies.

Authors:  Roland E Kontermann
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

6.  Effect of viscous drag on multiple receptor-ligand bonds rupture force.

Authors:  V K Gupta
Journal:  Colloids Surf B Biointerfaces       Date:  2012-06-07       Impact factor: 5.268

Review 7.  Research and development of next generation of antibody-based therapeutics.

Authors:  Jing Li; Zhenping Zhu
Journal:  Acta Pharmacol Sin       Date:  2010-08-09       Impact factor: 6.150

Review 8.  Antibody vectors for imaging.

Authors:  Tove Olafsen; Anna M Wu
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

9.  Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site.

Authors:  Thomas List; Dario Neri
Journal:  MAbs       Date:  2012-10-02       Impact factor: 5.857

10.  Fusion of Gaussia luciferase to an engineered anti-carcinoembryonic antigen (CEA) antibody for in vivo optical imaging.

Authors:  Katy M Venisnik; Tove Olafsen; Sanjiv S Gambhir; Anna M Wu
Journal:  Mol Imaging Biol       Date:  2007 Sep-Oct       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.